In a rapid turnaround, biotech firm Juno Therapeutics has been given the green light to resume testing a promising cancer therapy that involves genetically engineering patients’ immune systems.
Last week, the U.S. Food and Drug Administration ordered Juno to halt its trial of the treatment after three patients died. The company said the deaths were not the result of the immune cells, which are modified outside the body before being injected back into a patient, but of a toxic reaction to a preconditioning drug used as part of the treatment. That compound, fludarabine, has been removed from the protocol.
Juno’s stock rebounded on the news, after it had plunged 30 percent last week when the trial was stopped. Whether the company will be able to beat competitors Kite Pharma and Novartis to market remains to be seen. Juno had been planning on seeking FDA approval in 2017.
Initial trials for Juno’s therapy, known as CAR-T, have produced remarkable results in patients with recurrent acute lymphoblastic leukemia—about eight in 10 patients saw their tumors disappear. But the treatment is risky, so the tests have been limited to patients facing long odds of survival.
Forget dating apps: Here’s how the net’s newest matchmakers help you find love
Fed up with apps, people looking for romance are finding inspiration on Twitter, TikTok—and even email newsletters.
How AI is reinventing what computers are
Three key ways artificial intelligence is changing what it means to compute.
These weird virtual creatures evolve their bodies to solve problems
They show how intelligence and body plans are closely linked—and could unlock AI for robots.
We reviewed three at-home covid tests. The results were mixed.
Over-the-counter coronavirus tests are finally available in the US. Some are more accurate and easier to use than others.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.